The agency has given a thumbs up to Sanofi’s Merilog (insulin-aspart-szjj) as the first biosimilar to Novo Nordisk’s NovoLog for patients ... 38 million in the U.S. with diabetes, 8.4 million ...

The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

It calls the new drug “Merilog,” a biosimilar to the widely-used insulin product Novolog (insulin aspart). READ: Stem cells show promise in reversing type 1 diabetes The FDA defines a ...

President Trump announced an investment from Taiwan Semiconductor Manufacturing Co. of $100 billion in chip-manufacturing plants in the U.S. Photo: Samuel Corum/Bloomberg News WASHINGTON—Taiwan ...

During a hearing, representatives for the Newsom administration said they could not provide a timeline for when ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

SILVER SPRING, Md., Feb. 14, 2025 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes.

Merilog 100units/mL is supplied as both a 10mL multi-dose vial as well as a 3mL single-patient-use prefilled pen. The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj ...